BELLEROPHON THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

Item 8.01. Other Events.

On May 11, 2023, Bellerophon Therapeutics, Inc. issued a press release announcing that the last patient has completed the blinded treatment in the Phase 3 REBUILD Study for INOpulse® in fibrotic interstitial lung disease. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

Exhibit No.    Description
  99.1           Press Release dated May 11, 2023
104            Cover Page Interactive Data File (Formatted as Inline XBRL)


                                       2

© Edgar Online, source Glimpses